Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - nifedipine - tablet prolonged release - 20 mg milligram - nifedipine

United States - English - NLM (National Library of Medicine)

proficient rx lp - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine extended-release tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. nifedipine extended-release tablet is indicated for the management of chronic st

United States - English - NLM (National Library of Medicine)

leading pharma, llc - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine capsules, usp (nifedipine) is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine capsules, usp may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta-blockers. nifedipine capsules, usp is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate

Canada - English - Health Canada

pharmascience inc - nifedipine - tablet (extended-release) - 60mg - nifedipine 60mg - dihydropyridines

Canada - English - Health Canada

pharmascience inc - nifedipine - tablet (extended-release) - 30mg - nifedipine 30mg - dihydropyridines

Canada - English - Health Canada

mylan pharmaceuticals ulc - nifedipine - tablet (extended-release) - 60mg - nifedipine 60mg - dihydropyridines

Canada - English - Health Canada

mylan pharmaceuticals ulc - nifedipine - tablet (extended-release) - 30mg - nifedipine 30mg - dihydropyridines

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nifedipine, quantity: 60 mg - tablet, modified release - excipient ingredients: iron oxide red; titanium dioxide; hypromellose; magnesium stearate; povidone; purified talc; macrogol 4000; carbomer 934p; lactose monohydrate; colloidal anhydrous silica; basic butylated methacrylate copolymer - treatment of hypertension. prophylaxis of chronic stable angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nifedipine, quantity: 30 mg - tablet, modified release - excipient ingredients: carbomer 934p; titanium dioxide; povidone; purified talc; iron oxide red; macrogol 4000; hypromellose; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; basic butylated methacrylate copolymer - treatment of hypertension. prophylaxis of chronic stable angina pectoris.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 20mg (plus 10% overage) - modified release tablet - 20 mg - active: nifedipine 20mg (plus 10% overage) excipient: cellulose acetate hypromellose   iron oxide red macrogol 3350 magnesium stearate opacode black s-1-17823 opadry pink oy-s-24914 polyethylene oxide sodium chloride - treatment of coronary heart disease